Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 25 clinical trials
A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

The purpose of this trial is to assess the long-term safety of CAM2029 in patients with acromegaly. Patients will be administered CAM2029 subcutaneously once monthly during 12 months. Patients fulfilling trial NCT04076462 will be offered to continue with open-label treatment week 24-52 in this trial.

somatomedin c
igf1
hepatic disease
insulin-like growth factor
octreotide
  • 316 views
  • 15 Mar, 2022
  • 60 locations
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

The purpose of this trial is to assess the efficacy and safety of CAM2029 in patients with acromegaly. Patients will be randomized to either CAM2029 or placebo administered subcutaneously once monthly during 6 months.

somatomedin c
hepatic disease
insulin-like growth factor
octreotide
igf1
  • 79 views
  • 06 Mar, 2022
  • 59 locations
Role of Antisecretory Factor in Dihydropyrimidine Treatment of Colorectal Cancer (SALFLADMET)

in-hospital care including periods of support with iv fluids. The efficacy of current treatment for this adverse effect include iv fluids, loperamide and opioids po and octreotide sc is moderate and

  • 0 views
  • 01 May, 2022
  • 1 location
Acromegaly Combination Treatment Study

In this study the investigators will evaluate whether combination low dose somatostatin receptor ligand (SRL) and weekly or daily Pegvisomant will attain equivalent control of serum IGF-1 levels at a lower cost, compared to combination high dose SRL and weekly Pegvisomant. Lower doses of therapy will greatly reduce cost of …

pegvisomant
medical therapy
dopamine
lfts
insulin-like growth factor
  • 185 views
  • 04 Oct, 2021
  • 1 location
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (SORENTO)

The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who

  • 0 views
  • 16 May, 2022
  • 31 locations
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2)

The aim of NETTER-2 is to determine if Lutathera in combination with long-acting octreotide prolongs PFS in GEP-NET patients with high proliferation rate tumors (G2 and G3), when given as a

  • 0 views
  • 15 Mar, 2022
  • 40 locations
68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors

Somatostatin receptor (SSR) imaging is a critical component of clinical care for many patients being investigated for or with confirmed SSR positive tumors. In the past, 111In-octreotide imaging

  • 0 views
  • 03 May, 2022
  • 1 location
68Ga-DOTATATE PET for Management of Neuroendocrine Tumors

This is a research study to collect information regarding usefulness of positron emission tomography (PET) scans using a special dye called 68Ga-DOTATATE for patients with neuroendocrine tumours by determining the number of of patients whose clinical management was changed as a result of the scans.

pet/ct scan
positron emission tomography
conventional imaging
dotatate
  • 0 views
  • 05 Dec, 2021
  • 1 location
Stress Hydrocortisone In Pediatric Septic Shock (SHIPSS)

SHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded interventional trial that will examine the potential benefits and risks of adjunctive hydrocortisone prescribed for children with fluid and vasoactive-inotropic refractory septic shock. It is hypothesized that adjunctive hydrocortisone will significantly reduce the proportion of children with poor outcomes, defined as death …

antimicrobial agent
inotropic agent
norepinephrine
continuous infusion
  • 29 views
  • 16 May, 2022
  • 43 locations
Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients With Esophageal or Gastric Cancer

The aim of the study is to clarify whether octreotide therapy can reduce undesired postoperative weight loss, increase health-related quality of life and improve the appetite after surgery for

esophagectomy
gastrectomy
gastric cancer
  • 0 views
  • 25 Jun, 2021
  • 1 location